Retatrutide is a triple-agonist research peptide targeting GLP-1, GIP, and glucagon receptors for controlled in-vitro studies of metabolic regulation and energy balance pathways.
This research peptide is a synthetic amino acid sequence designed to act as a triple agonist at GLP-1, GIP, and glucagon receptors. Its structure and receptor-binding profile make it useful for exploring energy balance, metabolic regulation, receptor signalling, and endocrine pathway interactions in vitro.
